KRAS G12D Clinical Trials

3 recruiting

KRAS G12D Trials at a Glance

9 actively recruiting trials for kras g12d are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Zhengzhou, New York, and Hangzhou. Lead sponsors running kras g12d studies include Ranok Therapeutics (Hangzhou) Co., Ltd., Genfleet Therapeutics (Shanghai) Inc., and AstraZeneca.

Browse kras g12d trials by phase

Treatments under study

About KRAS G12D Clinical Trials

Looking for clinical trials for KRAS G12D? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new KRAS G12D trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about KRAS G12D clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Non-small Cell Lung CancerMetastatic Lung CancerMetastatic Lung Non-Small Cell Carcinoma+18 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Phase 2

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
The First Affiliated Hospital with Nanjing Medical University30 enrolled1 locationNCT07438106
Recruiting
Phase 1Phase 2

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Advanced Solid CancerKRAS G12D Mutation
Arvinas Inc.159 enrolled14 locationsNCT07023731
Recruiting
Phase 2

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Pancreatic Ductal Adenocarcinoma (PDAC)KRAS G12D Mutations
Ranok Therapeutics (Hangzhou) Co., Ltd.60 enrolled2 locationsNCT07303465
Recruiting
Phase 1

RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors

KRAS G12DT Cell Therapy
Henan Cancer Hospital30 enrolled1 locationNCT06546150
Recruiting
Phase 1

Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

Advanced KRAS G12D Mutant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.153 enrolled2 locationsNCT07134998
Recruiting
Phase 1Phase 2

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Advanced Solid TumorsKRAS G12D Mutations
Genfleet Therapeutics (Shanghai) Inc.407 enrolled20 locationsNCT06500676
Recruiting
Phase 1Phase 2

A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd.152 enrolled6 locationsNCT06667544